$13.750
-1.320 (-9.60%)Zum Schluss
BLSM im Vergleich zur Peergroup
In the context of the broader market, BLSM competes directly with industry leaders such as PHAT and EOLS. With a market capitalization of $436.98M, it holds a significant position in the sector. When comparing efficiency, BLSM's gross margin of N/A stands against PHAT's 78.32% and EOLS's 66.19%. Such benchmarking helps identify whether BlossomHill Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von BlossomHill Therapeutics Inc
The company reported a net income of -$23,758,000 in Q2 2026, reflecting ongoing losses, but it has a strong current ratio of 5.42, indicating good short-term financial health.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.